Valeant Pharmaceuticals Is Under S.E.C. Investigation by KATIE THOMAS

By KATIE THOMAS

The beleaguered drug maker, already under scrutiny for its steep price increases, earlier canceled its fourth-quarter earnings report.

Published: March 1, 2016 at 12:00AM

from NYT Business Day http://ift.tt/1QomMcB

from WordPress http://ift.tt/1QQwMAJ
via Hadi Aboukhater